TRCT
OREX

Tower Research Capital (TRC)’s Orexigen Therapeutics, Inc. OREX Stock Holding History

Tower Research Capital (TRC)’s Portfolio OREX Stock Details OREX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-9,173
Closed -$16K – 4653
2016
Q4 		$16K Buy
9,173
+3,707
+68% +$8.71K ﹤0.01% 2358
2016
Q3 		$18K Buy
5,466
+2,546
+87% +$9.62K ﹤0.01% 1703
2016
Q2 		$13K Sell
2,920
-748
-20% -$3.38K ﹤0.01% 2634
2016
Q1 		$21K Buy
3,668
+3,659
+40,656% +$47.5K ﹤0.01% 1327
2015
Q4 		$0 Buy
+9
New +$215 ﹤0.01% 5766
2015
Q3 		– Sell
-2,256
Closed -$111K – 5664
2015
Q2 		$111K Sell
2,256
-2,614
-54% -$156K 0.01% 723
2015
Q1 		$382K Buy
+4,870
New +$302K 0.05% 206
2014
Q4 		– Sell
-30
Closed -$1K – 5553
2014
Q3 		$1K Sell
30
-93
-76% -$4.99K ﹤0.01% 4334
2014
Q2 		$8K Buy
123
+53
+76% +$3.08K ﹤0.01% 2583
2014
Q1 		$5K Buy
+70
New +$4.74K ﹤0.01% 3384
2013
Q4 		– Sell
-859
Closed -$53K – 5531
2013
Q3 		$53K Buy
+859
New +$58.2K 0.01% 1876

Other funds holding OREX

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCMI
Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
GL
GLG LLC New York $1.39B AUM 24.01% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OWIM
Old West Investment Management Los Angeles, California $923M AUM 112.31% 1-Year Est. Return

Tower Research Capital (TRC)'s OREX Position: Q1 2017 in Review

Tower Research Capital (TRC) sold out of Orexigen Therapeutics, Inc. (OREX) in Q1 2017, closing a stake of 9,173 shares — an estimated $16K sold.

Tower Research Capital (TRC) first reported a position in OREX in Q3 2013 and held it in 11 quarters. The position peaked at $382K in Q1 2015. 52 funds tracked by Wall St. Rank hold OREX as of Q1 2017.

  • Tower Research Capital (TRC) reported no remaining Orexigen Therapeutics, Inc. position as of Q1 2017 after selling out during the quarter.
  • Tower Research Capital (TRC) sold 9,173 Orexigen Therapeutics, Inc. shares in Q1 2017, an estimated $16K.
  • Tower Research Capital (TRC) first reported a position in Orexigen Therapeutics, Inc. in Q3 2013 and held it in 11 quarters.
  • Tower Research Capital (TRC)'s Orexigen Therapeutics, Inc. position peaked at $382K in Q1 2015.
  • 52 funds tracked by Wall St. Rank held Orexigen Therapeutics, Inc. as of Q1 2017.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2017, filed 19 May 2017.